Larimar Therapeutics Inc (LRMR)

[Wildbilly]

Zafgen Presents Positive Safety and Efficacy Data

From Phase 2 Trial of Beloranib in Severe Obesity and Proof of Concept Trial in Prader-Willi Syndrome at ECO 2...

Poster Numbers: PO.111, PO.112

Beloranib Treatment Led to Rapid and Significant Weight Loss and Improvements in Cardiometabolic Biomarkers, Supports Potential to Improve Common Co-Morbid Conditions

PRAGUE, Czech Republic, May 8, 2015 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today announced positive efficacy and safety data from its ZAF-201 Phase 2 trial of beloranib, a MetAP2 inhibitor, in obese patients. The Company also announced efficacy and safety data from ZAF-211, a proof of concept study of beloranib in patients with Prader-Willi syndrome (PWS). These findings, presented at the 22nd European Congress on Obesity (ECO) on May 7-8, 2015 in Prague, Czech Republic, demonstrated meaningful weight loss and improvement in cardiometabolic biomarkers.

"We are very pleased to present these results to the European obesity research community from our trials in patients with severe obesity and PWS, which demonstrated that treatment with beloranib is not only safe, but also showed meaningful improvements in body weight in obese patients," said Thomas Hughes, Ph.D., Chief Executive Officer of Zafgen. "In both trials, beloranib treatment also improved a variety of biomarkers associated with cardiovascular disease risk and inflammation, supporting its potential to improve common co-morbid conditions affecting patients with obesity and PWS."

Beloranib is a novel, first-in-class injectable small molecule therapy with a unique mechanism of action that reduces drive to eat while stimulating the use of stored fat as an energy source.

"Significant reductions in total and LDL cholesterol and triglyceride levels and an increase in HDL cholesterol were noted in the beloranib 2.4 mg group. A significant increase in HDL cholesterol and decrease in triglyceride levels was observed with beloranib 1.2 mg. Consistent with reduced fat mass and improved adipose tissue function and inflammation, significant (p < 0.001) changes in adiponectin, leptin, and hs-CRP were observed with beloranib."

(Read more:) http://ir.zafgen.com/releasedetail.cfm?ReleaseID=912033



.